Orphazyme announces changes to the Board of Directors
Dec 9, 2021
Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021.
Orphazyme announces changes to the Board of Directors
Read moreFinancial Calendar 2022
Nov 19, 2021
Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to the following schedule.
Read moreOrphazyme establishes a U.S. At-the-Market Offering Program with Cowen
Nov 4, 2021
Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a prospectus supplement (“Prospectus”) relating to a U.S. At-the-Market Offering Program, pursuant to which the Company may issue and sell American Depositary Shares ("ADSs") having an aggregate offering price of up to $50,000,000, each ADS representing one ordinary share of the Company, to be sold in the United States at market price, from time to time, at its option, in “at the market” transactions on The Nasdaq Global Select Market (the “ATM Program”). The ADSs are intended to be sold pursuant to a Sales Agreement (the "Sales Agreement") with Cowen and Company, LLC ("Cowen"). The timing of any sales will depend on a variety of factors.
Orphazyme establishes a U.S. At the Market Offering Program with Cowen
Read moreOrphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C
Oct 31, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today provides an update on the regulatory status in the United States of its investigational product arimoclomol for Niemann-Pick disease type C (NPC) following a recently held Type A meeting with the U.S. Food and Drug Administration (FDA).
Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in NPC
Read moreModified long-term share-based incentive program for 2021
Oct 7, 2021
Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 (the “LTIP”) with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the Company’s shareholders.
Modified long term share based incentive program for 2021
Read moreOrphazyme provides regulatory and financial updates
Oct 5, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C (NPC). The company also announces that it now expects to end 2021 with a cash position of no less than DKK 80 million compared to prior guidance of approximately DKK 50 million.
Orphazyme provides regulatory and financial updates
Read moreOrphazyme reports business highlights and financial results in Interim Report First Half 2021
Aug 31, 2021
Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company, today announces its Interim Report First Half 2021 for the period January 1 – June 30, 2021.
Orphazyme reports business highlights and financial results in Interim Report First Half 2021
Read moreOrphazyme to host Interim Report First Half 2021 investor call on August 31, 2021
Aug 25, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces that the Company will host an investor call during which Management will present the Interim Report First Half 2021. The presentation will be followed by a Q&A session.
Orphazyme to host interim report first half 2021 inv
Read moreOrphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherited Metabolic Disease
Aug 23, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced that results from a Phase 2/3 trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) have been published in the peer-reviewed Journal of Inherited Metabolic Disease (JIMD). The online publication is available here.
Orphazyme announces publication of results from its
Read moreNew publication date for Orphazyme’s Interim Report H1 2021
Aug 5, 2021
Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a new publication date for Orphazyme’s Interim Report H1 2021, which is now being made public on August 31, 2021 (previously: August 24, 2021).
New publication date for Orphazyme’s Interim Report H1 2021
Read more